Ivabradine Krka

Ivabradine, the active ingredient in Ivabradine Krka, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is used to treat chronic stable angina and chronic heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradine Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine acts on the cardiac If current to manage conditions where heart‑rate reduction improves outcomes. - Chronic stable angina: improves exercise tolerance and reduces frequency of angina attacks. - Chronic heart failure with reduced ejection fraction (NYHA class II‑III): lowers heart rate, alleviates symptoms and may decrease hospitalisations. - Heart failure (NYHA class II‑III) with reduced ejection fraction: contributes to better functional capacity and quality of life.

Ivabradine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Luminous phenomena (phosphenes): transient visual disturbances. - Bradycardia: heart rate below the intended therapeutic range. - Headache. - Dizziness. - Fatigue. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic bradycardia requiring medical intervention. - Atrial fibrillation or other arrhythmias. - Severe hypotension. - Allergic reactions including rash or angioedema. - Visual disturbances persisting beyond transient phosphenes. - Myocardial ischaemia in susceptible patients.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for potential risks. - Heart rate monitoring: ensure resting heart rate remains above 50 bpm. - Avoid in severe hypotension: contraindicated when systolic blood pressure is <90 mmHg. - Caution in hepatic impairment: dose adjustment may be required. - Do not use in acute decompensated heart failure or unstable angina. - Contraindicated with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin). - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Ivabradine can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole): increase ivabradine plasma levels. - Other bradycardic agents (beta‑blockers, digoxin, diltiazem, verapamil): risk of excessive heart‑rate reduction. - Certain anti‑arrhythmic drugs (e.g., amiodarone) that affect cardiac conduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (fluconazole, erythromycin): may modestly raise ivabradine concentrations. - CYP3A4 inducers (rifampicin, carbamazepine, phenytoin): may reduce therapeutic effect. - Antihypertensive agents (ACE inhibitors, ARBs): monitor blood pressure for additive hypotensive effect. - Other anti‑anginal drugs (nitrates, ranolazine): assess for combined symptom control and side‑effect profile.